Clinical Trial Update: SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for brentuximab vedotin (SGN-35) in CD30-positive lymphoproliferative disorders, including primary cutaneous anaplastic large cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Anaplastic Large Cell Lymphoma
• Cutaneous T-cell Lymphoma
• Lymphomatoid Papulosis
• Mycosis Fungoides

Drugs mentioned

• Adcetris (Brentuximab vedotin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Lymphoma, Primary Cutaneous Anaplastic Large Cell | Phase 2 | Status: ACTIVE_NOT_RECRUITING